Image source: © 2025 Krish Capital Pty.Ltd

Highlights

  • Concorde International Group surged 75.10% following the announcement of a new equity incentive plan.
  • Boqii Holding rose 54.86% after completing a reverse stock split and share consolidation.
  • Taysha Gene Therapies gained 53.46%, supported by FDA breakthrough designation and employee stock grants.

On October 2, 2025, the US stock market closed with mostly small gains across major indices, despite ongoing concerns about a government shutdown. The Dow Jones Industrial Average ended up 0.17% at 46,519.72, the S&P 500 closed slightly higher, continuing its streak of record closes, and the Nasdaq saw notable gains driven by strength in technology and AI stocks.

Among the plethora of stocks, Concorde International Group Ltd, Boqii Holding Limited, and Taysha Gene Therapies, Inc. were among the most notable movers in recent trading of the US stock market, posting sharp percentage gains. Key corporate developments, including equity incentive plans, share restructuring, and regulatory milestones, have triggered heightened market activity across these small-cap stocks.

Concorde International Group Ltd (NASDAQ:CIGL) Equity Incentive Plan Spurs Significant Gains

Concorde International Group Ltd jumped more than 75% after regulatory filings revealed Board-approved 2025 Equity Incentive Plan that includes stock options and performance shares, covering up to 20% of outstanding shares for employees and directors. The company reported an 11% revenue increase to USD 6 million for the first half of 2025 and a gross profit rise of 30%. CEO and Chairman Swee Kheng Chua confirmed the disclosures which add to market interest following positive quarterly results.

Boqii Holding Limited (NYSE:BQ) Shares Climb After Reverse Split and Structural Changes

Boqii Holding Limited's shares advanced nearly 55% following a 1-for-160 reverse stock split aimed at simplifying its capital structure and securing regulatory compliance. The restructuring has facilitated Boqii’s transition to a direct NYSE listing from its previous American Depositary Shares (ADSs) format. Despite some revenue softness, operational improvements and margin expansion were noted in the latest fiscal update, supporting the stock’s move in active market sessions.

Taysha Gene Therapies (NASDAQ:TSHA) FDA Designation and Stock Grants Propel Stock

Taysha Gene Therapies gained over 53% after the FDA granted Breakthrough Therapy designation for the drug TSHA-102 targeting Rett syndrome. The company recently introduced stock option grants under its 2023 Inducement Plan to strengthen its talent resources. Positive clinical trial progress and regulatory feedback highlight the stock’s market momentum, marking it as a key biotech player under watch.